Literature DB >> 3020248

Cardiac glycosides. 7. Sugar stereochemistry and cardiac glycoside activity.

H Rathore, A H From, K Ahmed, D S Fullerton.   

Abstract

Digitoxigenin alpha-L-, beta-L-, alpha-D-, and beta-D-glucosides; alpha-L-, beta-L-, alpha-D-, and beta-D-mannosides; and alpha-L- and beta-L-rhamnosides were stereoselectively synthesized from the corresponding sugar tetrabenzyl trichloroacetimidates. The Na+,K+-ATPase receptor inhibitory activities of these glycosides (as a measure of receptor binding) were compared with those of digitoxigenin, digitoxigenin 6'-hydroxy-beta-D-digitoxoside, digitoxigenin beta-D-galactoside, and digitoxigenin beta-D-digitoxoside. The observed activities reveal that a given sugar substituent may have a role in binding of some glycoside stereoisomers, but not others. With alpha-L- and possibly beta-L-rhamnosides, the 5'-CH3 and 4'-OH appear to have a predominant role in binding to the Na+,K+-ATPase receptor. Addition of a 6'-OH to form the corresponding mannosides dramatically disrupts the effect of both the 5'-CH3 and 4'-OH in prompting receptor binding of the alpha-L isomer. However, with the beta-L isomer, some influence of 4'-OH, 3'-OH, and 2'-OH binding remains. With beta-D-glycosides, binding via the "5'-CH3 site" appears to be of little importance and addition of a 6'-OH diminishes activity only slightly. With these beta-D-glycosides, an equatorial 4'-OH, axial 3'-OH, and equatorial 2'-OH groups appear to contribute to binding.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3020248     DOI: 10.1021/jm00160a025

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  C5'-Alkyl Substitution Effects on Digitoxigenin α-l-Glycoside Cancer Cytotoxicity.

Authors:  Hua-Yu Leo Wang; Zhang Qi; Bulan Wu; Sang-Woo Kang; Yon Rojanasakul; George A O'Doherty
Journal:  ACS Med Chem Lett       Date:  2011-04-14       Impact factor: 4.345

2.  Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase.

Authors:  Adriana Katz; Yael Lifshitz; Elizabeta Bab-Dinitz; Einat Kapri-Pardes; Rivka Goldshleger; Daniel M Tal; Steven J D Karlish
Journal:  J Biol Chem       Date:  2010-04-13       Impact factor: 5.157

3.  Synthesis and Evaluation of the α-D-/α-L-Rhamnosyl and Amicetosyl Digitoxigenin Oligomers as Anti-tumor Agents.

Authors:  Hua-Yu Leo Wang; Yon Rojanasakul; George A O'Doherty
Journal:  ACS Med Chem Lett       Date:  2011-04-14       Impact factor: 4.345

4.  Stereochemical survey of digitoxin monosaccharides: new anticancer analogues with enhanced apoptotic activity and growth inhibitory effect on human non-small cell lung cancer cell.

Authors:  Hua-Yu Leo Wang; Wenjun Xin; Maoquan Zhou; Todd A Stueckle; Yon Rojanasakul; George A O'Doherty
Journal:  ACS Med Chem Lett       Date:  2011-01-13       Impact factor: 4.345

5.  Crystal structure of the sodium-potassium pump (Na+,K+-ATPase) with bound potassium and ouabain.

Authors:  Haruo Ogawa; Takehiro Shinoda; Flemming Cornelius; Chikashi Toyoshima
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

6.  Digitalis receptor sugar binding site characteristics: a model based upon studies of Na+, K(+)-ATPase preparations with differing digitalis sensitivities.

Authors:  A H From; D S Fullerton; K Ahmed
Journal:  Mol Cell Biochem       Date:  1990-05-10       Impact factor: 3.396

7.  Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization.

Authors:  Joseph M Langenhan; Noël R Peters; Ilia A Guzei; F Michael Hoffmann; Jon S Thorson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-16       Impact factor: 11.205

8.  Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na+/K+-ATPase.

Authors:  Laetitia Moreno Y Banuls; Adriana Katz; Walter Miklos; Alessio Cimmino; Daniel M Tal; Elena Ainbinder; Martin Zehl; Ernst Urban; Antonio Evidente; Brigitte Kopp; Walter Berger; Olivier Feron; Steven Karlish; Robert Kiss
Journal:  Mol Cancer       Date:  2013-04-26       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.